ReviewJournal of the Egyptian National Cancer Institute2026
Serum biomarkers as personalised medicine for diagnostic and therapeutic approaches of hepatocellular carcinoma.
Review in Journal of the Egyptian National Cancer Institute, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is a critical public health concern due to its rising incidence and mortality. Early diagnosis is challenging due to nonspecific symptoms and limitations of traditional methods. This study explores the potential of three key biomarkers, serum alpha-fetoprotein (AFP), des-γ-carboxyprothrombin (DCP), and glypican-3 (GPC3), in advancing personalized medicine for HCC, focusing on their roles in diagnostics and therapeutics. We conducted a literature review using specific keywords to narrow our search. Our findings indicate that AFP and DCP are primarily used for diagnostics, while GPC3 serves both diagnostic and therapeutic purposes. AFP is commonly used in late-stage detection due to its limited sensitivity and specificity in early stages, which can lead to false diagnoses. DCP plays a significant role as both a diagnostic tool and therapeutic target, while GPC3 is used to differentiate malignant from non-cancerous liver tissues. The review highlights the mechanisms, roles, and personalised treatments associated with these biomarkers, while also addressing challenges such as biopsy issues and funding limitations. In conclusion, the development and improvement of AFP, DCP, and GPC3 as biomarkers for the diagnostics and treatment of HCC are important. Thus, their limitations should be addressed as these biomarkers play a crucial role in modern cancer therapy and are critical for increasing the survival rates of HCC patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.